Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9

British Journal of Pharmacology

Volumn 137, Issue 5, 2002, Pages 701-709

  Loadman, P M ^a   Bibby, M C ^a   Phillips, R M ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Bioreductive drugs; EO9; Mitomycin C; NQO1

Indexed keywords

2,5 DIAZIRIDINYL 3,6 DIMETHYL 1,4 BENZOQUINONE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; MEDZQ; MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENCY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; AZIRIDINES; DRUG DELIVERY SYSTEMS; HUMANS; INDOLEQUINONES; INDOLES; MICE; MICE, NUDE; QUINONES; TECHNOLOGY, PHARMACEUTICAL; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036850427     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704916     Document Type: Article

References (40)

1. Adams, G.E., Stratford, I.J., Edwards, H.S., Bremner, J.C.M. & Cole, S. (1992). Bioreductive drugs as post radiation sensitizers: Comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9. Int. J. Radiat. Oncol. Biol. Phys., 22, 717-720.
2. Bailey, S.M., Wyatt, M.D., Friedlos, F., Hartley, J.A., Knox, R.J., Lewis, A.D. & Workman, P. (1997). Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. Br. J. Cancer, 76, 1596-1603.
3. Beall, H.D., Mulchahy, T., Siegel, D., Traver, R.D., Gibson, N.W. & Ross, D. (1994). Metabolism of bioreductive antitumour compounds by purified rat and human DT-diaphorase. Cancer Res., 54, 3196-3201.
4. Beall, H.D., Murphy, A.M., Siegel, D., Hargreaves, R.H.J., Butler, J. & Ross, D. (1995). Nicotinamide adenine dinucleotide (phosphate):quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumour quinones: Quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol. Pharmacol., 48, 499-504.
5. Beall, H.D., Winski, S., Swann, E., Hudnott, A.R., Cotterill, A.S., O'Sullivan, N., Green, S.J., Bien, R., Siegel, D., Ross, D. & Moody, C.J. (1998). Indolequinone antitumour agents: Correlation between quinone structure, rate of metabolism by recombinant human NQO1 and in vitro cytotoxicity. Bioorg. Med. Chem. Lett., 8, 545-548.
6. Bibby, M.C., Cronin, B.P. & Phillips, R.M. (1993). Evaluation of the cytotoxicity of the indolequinine EO9 in a human colon adenocarcinoma model. Int. J. Oncology, 3, 661-666.
7. Choudry, G.A., Hamilton-Stewart, P.A., Double, J.A., Krul, M.R.L., Naylor, B., Flannigan, G.M., Shah, T.K., Brown, J.E. & Phillips, R.M. (2001). A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br. J. Cancer, 85, 1137-1146.
8. Collard, J., Matthew, A.M., Double, J.A. & Bibby, M.C. (1995). EO9: Relationship between DT-diaphorase levels and response in vitro and in vivo. Br. J. Cancer, 71, 1199-1203.
9. Cowan, D.S.M., Hicks, K.O. & Wilson, W.R. (1996). Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br. J. Cancer, 74 (Suppl XXVII), S28-S31.
10. Cummings, J., Spanswick, V.J., Gardiner, J., Ritchie, A. & Smyth, J. (1998). Pharmacological and biochemical determinants of the antitumour activity of the indolequinone EO9. Biochem. Pharmacol., 55, 253-260.
11. Dirix, L.Y., Tonnesen, F., Cassidy, J., Epelbaum, R., Ten Bokkel Huinink, W.W., Pavlidis, N., Sorio, R., Gamucci, T., Wolff, I., Te Velde, A., Lan, J. & Verweij, J. (1996). EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur. J. Cancer, 32, A2019-A2022.
12. Fitzsimmons, S.A., Workman, P., Grever, M., Paull, K., Camalier, R. & Lewis, A.D. (1996). Reductase enzyme expression across the National Cancer Institute tumour cell line panel: Correlation with sensitivity to mitomycin C and EO9. J. Natl. Cancer Inst., 88, 259-269.
13. Hendriks, H.R., Pizao, P.E., Berger, D.P., Kooistra, K.L., Bibby, M.C., Boven, E., Dreef-van der Meulen, H.C., Henrar, R.E., Fiebig, H.H., Double, JJ.A., Hornstra, H.W., Pinedo, H.M., Workman, P. & Schwartsmann, G. (1993). EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Euro. J. Cancer, 29, A897-906.
14. Jaffar, M., Naylor, M.A., Robertson, N., Lockyer, S.D., Phillips, R.M., Everett, S.A., Adams, G.E. & Stratford, I.J. (1998). 5-Substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en-1-ol (EO9, NSC 382459) and their regioisomers as hypoxia selective agents: Structure cytotoxicity in vitro. Anticancer Drug Des., 12, 105-123.
15. Loadman, P.M., Phillips, R.M., Lim, L.E. & Bibby, M.C. (2000). Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. Biochem. Pharmacol., 59, 831-837.
16. Malkinson, A.M., Siegel, D., Forrest, G.L., Gazdar, A.F., Oil, H.K., Chan, D.C., Bunn, P.A., Mabry, M., Dykes, D.J., Harrison, S.D. & Ross, D. (1992). Elevated DT-diaphorase activity and messenger-RNA content in human non-small-cell lung-carcinoma-relationship to the response of lung-tumour xenografts to mitomycin-C. Cancer Res., 52, 4752-4757.
17. Naylor, M.A., Swann, E., Everett, S.A., Jaffar, M., Nolan, J., Robertson, N., Lockyer, S.D., Patel, K.B., Dennis, M.F., Stratford, M.R.L., Wardman, P., Adams, G.E., Moody, C.J. & Stratford, I.J. (1998). Indolequinone antitumour agents: Reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl) methyl derivatives and hypoxia selective cytotoxicity in vitro. J. Med. Chem., 41, 2720-2731.
18. Oostveen, E.A. & Speckamp, W.N. (1987). Mitomycin analogs. 1. Indoloquinones as (potential) bisalkylating agents. Tetrahedron, 43, 255-262.
19. Pavlidis, N., Hanauske, A.R., Gamucci, T., Smyth, J., Lehnert, M., Te Velde, A., Lan, J. & Verweij, J. (1996). A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: A study of the EORTC Early Clinical Studies Group (ECSG). Ann. Oncol., 7, 529-531.
20. Phillips, R.M. (1996). Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-β-en-α-ol (EO9) by human DT-diaphorase. Biochem. Pharmacol., 52, 1711-1718.
21. Phillips, R.M., Bibby, M.C. & Double, J.A. (1990). A critical appraisal of the predictive value of in vitro chemosensitivity assays. J. Natl. Cancer Inst., 82, 1457-1468.
22. Phillips, R.M., Burger, A.M., Loadman, P.M., Jarrett, C.M., Swaine, D.J. & Fiebig, H.H. (2000). Predicting tumour response to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumour homogenates: Implications for enzyme directed bioreductive drug development. Cancer Res., 60, 6384-6390.
23. Phillips, R.M. & Clayton, M.R.K. (1997). Plateau phase cultures: An experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours. Br. J. Cancer, 75, 196-201.
24. Phillips, R.M., Hulbert, P.B., Bibby, M.C., Sleigh, N.R. & Double, J.A. (1992). In vitro activity of the novel indoloquinone EO9 and the influence of pH on cytotoxicity. Br. J. Cancer, 65, 359-364.
25. Phillips, R.M., Loadman, P.M. & Cronin, B.P. (1998). Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br. J. Cancer, 77, 2112-2119.
26. Phillips, R.M. & Ward, T. (2001). Influence of extracellular pH on the cytotoxicity and DNA damage of a series of indolequinone compounds. Anticancer Res., 21, 1795-1802.
27. Plumb, J.A., Gerritsen, M. & Workman, P. (1994). DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br. J. Cancer, 70, 1136-1143.
28. Plumb, J.A. & Workman, P. (1994). Unusually marked hypoxic sensitisation to indoloquinone EO9 and Mitomycin C in a human colon cell line that lacks DT-diaphorase activity. Int. J. Cancer, 56, 134-139.
29. Robertson, N., Haigh, A., Adams, G.E. & Stratford, I.J. (1994). Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur. J. Cancer, 30, A1013-A1019.
30. Roed, H., Aabo, K., Vindelov, L., Spang-Thomsen, M., Christenesen, I.J. & Hansen, H. (1989). In vitro and in vivo evaluation of the indolequinone EO-9 (NSC 382459) against human small cell carcinoma of the lung. Eur. J. Cancer Clin. Oncol., 25, 1197-1201.
31. Saunders, M., Jaffar, M., Patterson, A.V., Nolan, J., Naylor, M.A., Phillips, R.M., Harris, A.L. & Stratford, I.J. (2000). The relative importance of NADPH:Cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO-9 and related analogues lacking functionality at the C-2 and C-3 positions. Biochem. Pharmacol., 59, 993-996.
32. Schellens, J.H.M., Planting, A.S.T., van Acker, B.A.C., Loos, W.J., de Boer-Dennert, M., van der Burg, M.E.L., Koier, I., Krediet, R.T., Stoter, G. & Verweij, J. (1994). Phase I and pharmacological study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J. Natl. Cancer Inst., 86, 906-912.
33. Siegel, D., Gibson, N.W., Preusch, P.C. & Ross, D. (1990). Metabolism of MMC by DT-diaphorase: Role in MMC induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res., 50, 7483-7489.
34. Skibo, E.B., Gordon, S., Bess, L., Boruah, R. & Heileman, M.J. (1997). Studies of pyrrolo[1,2-alpha]benzimidazolequinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation. J. Med. Chem., 40, 1327-1339.
35. Tannock, I.F. & Rotin, D. (1989). Acid pH in tumours and its potential for therapeutic exploitation. Cancer Res., 49, 4373-4384.
36. Walton, M.I., Bibby, M.C., Double, J.A. & Workman, P. (1992). DT-diaphorase activity correlates with sensitivity to the indolequinone EO9 in mouse and human colon carcinomas. Eur. J. Cancer, 28, A1597-A1600.
37. Walton, M.I., Smith, P.J. & Workman, P. (1991). The role of NAD(P)H quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent EO9. Cancer Communications, 3, 199-206.
38. Wilson, W.R. & Hicks, K.O. (1999). Measurement of extravascular drug diffusion in multicellular layers. Br. J. Cancer, 79, 1623-1626.
39. Workman, P. (1994). Enzyme directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolising enzymes, particularly DT-diaphorase. Oncol. Res., 6, 461-475.
40. Workman, P., Twentyman, P., Balkwill, F., Balmain, A., Chaplin, D., Double, J., Embleton, J., Newell, D., Raymond, R., Stables, J., Stephens, T. & Wallace, J. (1998). United Kingdom co-ordinating committee on cancer research (UKCCCR), guidelines for the welfare of animals in experimental neoplasia (2nd edn.). Br. J. Cancer, 77, 1-10.